Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Sber, T-bank and Alfa-Bank set up a payment consortium operator

1/13/25 T

Sber, T-bank and Alfa-Bank set up a payment consortium operator

1/13/25 SBER

MGKL revenue to quadruple in 2024

1/13/25 MGKL

Joint project of Lukoil and Gazprom hit by sanctions

1/10/25 LKOH

Gazprom Shelfproject and RusGazAlliance are on the sanctions list

1/10/25 GAZP

Polar Lithium has fallen under sanctions

1/10/25 GMKN

Gazprom's LNG plant on the Baltic Sea hit by sanctions

1/10/25 GAZP

USA extends sanctions against Arctic LNG 2

1/10/25 NVTK

Sovcomflot vessels hit by sanctions

1/10/25 FLOT

US imposed sanctions on Gazprom Neft's subsidiaries

1/10/25 SIBN